Scandinavian Journal of Rheumatology · 2005 · 56 citations · 8 references
MedicineHematologyPharmacologyAutoimmunityClinical PharmacologyRheumatologyAdverse Drug Reaction ReportingAutoimmune DiseasesHematologic ToxicityImmune-related Adverse EventsPsoriatic ArthritisRheumatoid ArthritisAdverse Drug Reaction AnalysisBone Marrow Suppression ManagementImmune-mediated CytopeniasMedian AgeMortality CausesPemphigus ComplexPsoriatic DiseaseSerum Creatinine Assessment
OBJECTIVE: To study cases of low-dose methotrexate-induced pancytopenia with special reference to clinical outcome and factors predisposing to bone marrow suppression. METHODS: Patient files of 14 cases of methotrexate-induced pancytopenia reported to the National Agency for Medicines in Finland from 1991 to 1999 were reviewed. A review of four additional cases was included. RESULTS: Of the 18 patients (median age 72 years), 12 had rheumatoid arthritis, one psoriatic arthritis, five psoriasis without arthritis, and one pemphigus erythematosus. Major co-morbidity was recorded in 12 patients, and 16 patients used significant concomitant drugs. Eight patients had a mildly or moderately elevated serum creatinine concentration. In every patient the occurrence of cytopenia was abrupt. Eight patients (44%) died, and the most frequent cause of death was infection. CONCLUSIONS: Our data show that methotrexate-induced pancytopenia is associated with high mortality especially in cases with significant co-morbidity and concomitant medications.
8
Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis
Sergio Gutiérrez‐Ureña, José Fernando Molina, M L Cuéllar et al. · Arthritis & Rheumatism · 1996 · 280 citations
Efficacy of Methotrexate in Rheumatoid Arthritis
Michael E. Weinblatt · Lara D. Veeken · 1995 · 55 citations